Reduced Intensity Conditioning (RIC) transplantation is increasingly offered to older patients with acute myeloblastic leukemia (AML). We have previously shown that a RIC allograft, particularly from a sibling donor is beneficial in intermediate risk patients aged 35-65 years. We here present analyses from the NCRI AML16 trial extending this experience to older patients aged 60-70 inclusive lacking favorable risk cytogenetics 932 patients were studied, with RIC transplant in first remission given to 144 (sibling n=52, MUD n=92) with median follow-up for survival from CR of 60 months. Comparisons of transplant versus not are carried out using Mantel-Byar analysis. Among the 144 allografts, 93 had intermediate risk cytogenetics, 18 adverse and 33 were unknown. In transplanted patients survival was 37% at 5 years, and while the survival for siblings (44%) was better than that for MUDs (34%) this was not significant (p=0.2). When comparing RIC versus chemotherapy survival was significantly improved (37% vs 20%, HR 0.67 (0.53-0.84) p.

中文翻译：

---

接受低强度移植治疗急性髓细胞白血病的 60 至 70 岁老年患者的结果：NCRI 急性髓细胞白血病 16 试验的结果。


越来越多的老年急性髓细胞白血病 (AML) 患者接受低强度训练 (RIC) 移植。我们之前已经证明，RIC 同种异体移植物，特别是来自兄弟姐妹捐赠者的移植物，对于 35-65 岁的中危患者是有益的。我们在此介绍 NCRI AML16 试验的分析，将这一经验扩展到 60-70 岁（含）缺乏有利风险细胞遗传学的老年患者。对 932 名患者进行了研究，其中 144 名患者（兄弟姐妹 n=52，MUD n=92）在第一次缓解时接受了 RIC 移植， CR 后随访中位生存期为 60 个月。使用Mantel-Byar 分析对移植与非移植进行比较。在 144 例同种异体移植物中，93 例具有中等风险细胞遗传学，18 例不良，33 例未知。移植患者的 5 年生存率为 37%，虽然兄弟姐妹的生存率 (44%) 优于 MUD 的生存率 (34%)，但这并不显着 (p=0.2)。比较 RIC 与化疗时，生存率显着提高（37% vs 20%，HR 0.67 (0.53-0.84) p）。